Incretin-Based Drugs Market Growth Is Accelerating As Industry Transformation Continues
Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Incretin-Based Drugs Market Growth Analysis: How Will Revenue Expand During The Forecast Period?
The incretin-based drugs market has experienced robust expansion over recent years. Projected to increase from $27.83 billion in 2025 to $29.88 billion in 2026, it is advancing at a compound annual growth rate (CAGR) of 7.4%. Historical growth has been driven by the rising prevalence of type 2 diabetes, higher insulin resistance rates, metabolic disorders linked to lifestyle choices, broader adoption of endocrinology medications, and the implementation of hospital-based diabetes initiatives.
The market for incretin-based drugs is projected to experience significant expansion over the coming years, reaching a valuation of $39.25 billion by 2030 with a compound annual growth rate (CAGR) of 7.1%. This anticipated growth in the forecast period is driven by factors such as the global obesity crisis, rising demand for weight management medications, advancements in long-acting incretin formulations, a shift toward personalized diabetes treatments, and an increased emphasis on preventive metabolic health. Key trends shaping this period include the widespread uptake of GLP-1 receptor agonists, the broadening of therapeutic indications to encompass obesity management, a growing preference for oral incretin therapies, the emergence of combination treatment strategies, and enhanced patient compliance facilitated by once-weekly dosing schedules.
Download A Free Sample Report For Comprehensive Market Insights:
Incretin-Based Drugs Market Expansion Supported By Key Demand Factors
The anticipated growth of the incretin-based drugs market is being driven forward by the increasing incidence of type 2 diabetes mellitus. This condition, a chronic metabolic disorder marked by insulin resistance and impaired insulin secretion, results in elevated blood glucose levels. Its prevalence stems from poor dietary habits and physical inactivity, which foster insulin resistance and reduce the body’s capacity to regulate blood sugar effectively. Incretin-based drugs address type 2 diabetes by enhancing insulin release following meals and suppressing glucagon production, thereby lowering blood sugar. Additionally, they slow gastric emptying and reduce appetite, contributing to improved glucose control and weight loss. As an illustration, the National Health Service, a UK government department, reported in June 2024 that around 549,000 more people in England were at risk of developing type 2 diabetes in 2023, pushing the total number with pre-diabetes above 3.6 million—a nearly 20% increase from 2022. Consequently, the rising prevalence of type 2 diabetes mellitus is propelling the expansion of the incretin-based drugs market.
Incretin-Based Drugs Market Segmentation Trends And Revenue Drivers
The incretin-based drugs market covered in this report is segmented –
1) By Type: Glucagon-Like Peptide-1 Receptor (GLP-1) Agonists, Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
2) By Route Of Administration: Oral, Injectable
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
4) By Application: Type 2 Diabetes, Obesity, Other Applications
Subsegments:
1) By Glucagon-Like Peptide-1 Receptor (GLP-1) Agonists: Exenatide, Liraglutide, Dulaglutide, Semaglutide, Lixisenatide
2) By Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: Sitagliptin, Saxagliptin, Linagliptin, Alogliptin, Vildagliptin
Incretin-Based Drugs Market Growth Trends Influencing Competitive Dynamics
Major players in the incretin-based drugs market are now prioritizing the development of generic drug versions to provide patients with more effective and user-friendly treatment options for type 2 diabetes. A generic drug contains identical active ingredients, strength, dosage form, and administration route as its brand-name counterpart, yet it is sold under its chemical name without any brand labeling. For example, in December 2024, Hikma Pharmaceuticals PLC, a pharmaceutical firm headquartered in the UK, introduced the first generic version of Victoza (liraglutide) injection, 6 mg/mL, in the United States. This product gained approval from the Food and Drug Administration (FDA) and was indicated as a supplement to diet and exercise for improving glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes. By delivering a fresh and more affordable choice, it addresses the current shortages of GLP-1 medications.
Incretin-Based Drugs Market Industry Leaders: Which Organizations Are Driving Competition?
Major companies operating in the incretin-based drugs market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, AbbVie Inc., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Amgen Inc., Novo Nordisk A/S, Viatris, Boehringer Ingelheim GmbH, Astellas Pharma Inc., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd., Sumitomo Dainippon Pharma Co. Ltd., Hikma Pharmaceuticals PLC, Lupin Limited, Mitsubishi Tanabe Pharma Corporation
Access The Complete Incretin-Based Drugs Market Report:
Incretin-Based Drugs Market Regional Outlook: Where Are The Largest Opportunities Located?
North America was the largest region in the incretin-based drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the incretin-based drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
